| NCT ID | NCT05599139 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Medical Center Groningen |
| Condition | Differentiated Thyroid Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 25 participants |
| Start Date | 2023-02-22 |
| Primary Completion | 2026-03-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 25 participants in total. It began in 2023-02-22 with a primary completion date of 2026-03-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to compare the difference in thyroid uptake of a low dose radioactive iodine (10 MBq 123-I or 37 MBq 123-I) in athyreotic patients with differentiated thyroid carcinoma before and after a low iodine diet (LID) of 7 days. The main question it aims to answer is: • What is the difference in iodine uptake before and after a LID of 7 days? Uptake of a low dose of 123-iodine will be measured in participants before and after a low iodine diet of 7 days. Researchers will compare the uptake (%) before and after the LID.
Eligibility Criteria
Inclusion Criteria: * Patients, men and women above the age of 18 years, have to be diagnosed with DTC and have to follow a LID prior to the 131I ablation therapy according to the Dutch DTC guideline * Patients have to be fit to adhere to the study protocol * Patients have to be able to read and understand the Dutch language Exclusion Criteria: * Age \< 18 years * Patients using amiodarone * Patients receiving iodinated contrast \< 3 months before the LID * Pregnancy * Patients prepared for ablation therapy with rhTSH * Renal impairment, EGFR \<30ml/min/1,73m2
Contact & Investigator
Wouter Zandee, Dr.
PRINCIPAL INVESTIGATOR
University Medical Center Groningen
Frequently Asked Questions
Who can join the NCT05599139 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Differentiated Thyroid Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05599139 currently recruiting?
Yes, NCT05599139 is actively recruiting participants. Contact the research team at w.t.zandee@umcg.nl for enrollment information.
Where is the NCT05599139 trial being conducted?
This trial is being conducted at Groningen, Netherlands.
Who is sponsoring the NCT05599139 clinical trial?
NCT05599139 is sponsored by University Medical Center Groningen. The principal investigator is Wouter Zandee, Dr. at University Medical Center Groningen. The trial plans to enroll 25 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.